QualityStocks would like to highlight Celsion Corporation (NASDAQ: CLSN), an oncology drug development company engaged in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer.
In the company’s news yesterday,
Celsion Corporation announced that the independent Data Monitoring Committee (DMC) for its HEAT Study has completed a regularly scheduled review of the 701 patients enrolled in the trial and unanimously recommends that the HEAT Study continue according to protocol to its final data readout. The HEAT Study, being conducted under a Special Protocol Assessment (SPA) agreed to with the FDA, is a fully enrolled, multinational, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC or primary liver cancer).
Progression-free survival (PFS), the HEAT Study’s primary endpoint, is defined in the SPA. In total, 380 PFS events are required for reaching the unblinding and planned final analysis of the study. The company reaffirmed that 380 PFS events are projected to occur during the fourth quarter of 2012, with topline results to be announced after DMC review and confirmation.
Study data has been reviewed by the DMC at regular intervals, with the chief responsibilities of ensuring enrolled patient safety, collected data quality, and continued scientific validity of the study design. As part of its review of the 701 enrolled patients, the DMC monitored a quality matrix relating to the total clinical data set – confirming timely data collection and that all data are current, as well other data collection and quality criteria.
The HEAT Study is the single largest study that has ever been conducted in intermediate-stage primary liver cancer, which is currently the largest unaddressed cancer in oncology. Celsion has the regulatory, manufacturing, financial, and commercial plans and resources in place to ensure success once the HEAT Study’s outcome has been determined. Going forward, the company is confident in ThermoDox’s potential to offer a new and essential therapeutic option for patients suffering with this form of cancer.
In addition to being conducted under an FDA Special Protocol Assessment, the HEAT Study has also received FDA Fast Track designation and has been designated a “Priority Trial” for liver cancer by the National Institutes of Health. ThermoDox has received orphan drug designation in the United States and Europe, and the European Medicines Agency (EMA) has confirmed that the HEAT Study provides an acceptable basis for submission of a marketing authorization application for centralized review and approval. In addition to meeting the enrollment objectives of the FDA and EMA, the HEAT Study has also enrolled a sufficient number of patients to support registration filings in China, South Korea and Taiwan – three additional large and significant markets for ThermoDox.
Celsion, a leading oncology company, is committed to developing and commercializing innovative cancer drugs, including tumor-targeting treatments, using focused heat energy combined with heat-activated liposomal drug technology. The company has research, license, or commercialization agreements with leading institutions that include the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital, and the University of Oxford.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.